Akonni Biosystems Inc. and Chinese in vitro diagnostics company, Righton, announce a commercial agreement that enables Righton to sell Akonni’s products for nucleic acid purification and molecular diagnostics to researchers, clinical laboratories, and hospitals in China. The products to be sold include TruTip®, Akonni’s best-in-class sample preparation technology, which is low-cost and simple, yet highly effective at purifying DNA and RNA from the most difficult sample types. In addition, for diagnostic applications, Righton plans to commercialize Akonni’s TruDiagnosis® system based on the proprietary TruArray® multiplexed diagnostic solutions. Righton has made an equity investment of $7.5 million USD in Akonni’s series D fundraising round bringing the total investments in the Series D round to $13.9 million USD.